that's right, teva! but now teva has two main problems.ith the generic side of the business and the other with the branded one. in terms of the branded drug, let's just say, it accounts for 47% of the company sales. and it's just like any other phrma outfit. that's right. they have branded medicine. well, guess what. teva is finally getting a taste of its own medicine. the company has one huge drug called copaxone for multiple sclerosis, $3.8 billion in sales last year counted for 19% of the company's total revenues. likely to face tough competition, a new ms drug, i profiled last week. it was two weeks ago. the stock is up very, very big. but the big worry here is simply that copaxone's patent only lasts through 2015, two years from now. and some terms start to expire next year. in other words, teva is about to fall off a gigantic patent cliff of its own! as other generic drug makers swoop in to copy copaxone and crush the price of a drug that now really represents about -- geez, represents about a fifth of the company sales. teva is now

teva is a huge company.r, but not in replagues to plan b, one step. >> i don't know anything about that stock at all, but i have he' been watching it and they also are in the generic cholesterol market and this company makes a lot of wise decisions knowing when a pill is becoming hot. wouldn'ten surprised to see them move. stuart: look at that, up 7%-- i'm sorry, that's, i'm sorry, this is separate. that's morrison, that is totally separate, that's a family home building company. totally separate from this discussion. back to the plan b one step. you're out of it, not in the picture. i find it incredible that this kind of drug, a powerful drug, could be just handed over, over-the-counter, along with bubble gum, to someone of any age. you're out of the picture. >> that's the biggest problem of all because doctors have to play a role with young women deciding if they're going to become sexually active no matter what age. risk of sexually transmitted diseases. are they going to use condoms, tell their parents w

there's a huge uptick in search for teva sandals, chanel sunglasses and plus-sized swimsuits.p retail trade right now. >> can i give you two? one is t.j., we've liked that for a long time. the management was around visiting with investors recently. they have a very good story to tell. store growth, international growth and doing better in terms of e-commerce. nordstrom is the other one. they're doing aggressive reinvestment into their business, also to grow double digits and returns as well. >> steve weiss? >> i'm going to assume your closet is now full given the searches we just saw that you're fully accounted for. >> thank you. >> basically i think you want to stay with what's been working. that is macy's, abercrombie & fitch is going to cut costs. that's one you could play. stay with the retailers that have the edge. stay away from the fashion -- real fashion. i also like kors. >> dr. "j," a quick retail trade for me? >> gap because of old navy primarily but also because of ban ana republic. >>> courtney reagan and her guests will talk about the weather and what's on the mi

the ruling gives the f.d.a. 30 days to lift the age restrictions on teva pharmaceutical's plan-b one step' and its generic form. under current regulations, the emergency contraceptive, which reduces the risk of pregnancy by half if taken soon after unprotected sex, is only available over-the-counter to women 17 or older. younger teenagers must have a prescription. in 2011, the f.d.a. concluded plan-b one step was safe to sell to everyone without that requirement. but health and human services secretary kathleen sebelius overruled that decision, saying there was not enough evidence to allow the contraceptive to be sold to girls younger than 17 without a doctor's order. today, u.s. district judge edward korman called that action "arbitrary, capricious, and unreasonable-- an excuse to deprive the overwhelming majority of women of their rights to obtain contraceptives without unjustified and burdensome restrictions." in response, this afternoon in washington, white house press secretary jay carney said the administration stands by its original decision. >> secretary sebelius made this de

an advocacy groups, petitioning the fda to make this available, and we also have the manufacturer, teva, which makes the morning after pill, also try to gain the ability to sell it over the counter. we had multiple things going on. made commentsally suggesting this should be available to everyone and it is safe, potentially save. hadhe same time, we kathleen sebelius said perhaps this should not be available, young girl should not be allowed to attain it. -- first we had a lawsuit in 2005 which culminated with the judge ruling that this should be made 17,lable to women at least and then following that, -- misinformation for pharmacies in terms of who could access this without a prescription. this seems to be cause to reopen the case, and that is what led to the ruling now. host: this is an issue that came out yesterday at the white house briefing. we are going to hear jay carney talk about the ruling yesterday. >> secretary sebelius made the decision, so i would refer you to her office on the policy specifics, but when the secretary made the decision, the president supported it, believe